CLINICAL STUDY

Pegvisomant interference in GH assays results in underestimation of GH levels

A N Paisley, K Hayden², A Ellis³, J Anderson¹, G Wieringa¹ and P J Trainer

Department of Endocrinology, Christie NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK, ¹Department of Biochemistry, Christie Hospital, Manchester, UK, ²Department of Clinical Biochemistry, University Hospital Aintree, Liverpool, UK and ³UK NEQAS, Department of Clinical Biochemistry, Royal Infirmary, Edinburgh, UK

(Correspondence should be addressed to P J Trainer; Email: peter.trainer@man.ac.uk)

Abstract

Introduction: Pegvisomant use in acromegaly negates the use of GH levels to monitor disease activity. To achieve antagonism, plasma concentrations must be ~1000-fold greater than GH which with the high homology between the peptides makes GH measurement a challenge when pegvisomant is present.

Objective: We investigated the effect of pegvisomant on GH measured using commercially available assays.

Methods: Pooled serum samples with GH concentrations <0.38, 3.85 and 7.69 µg/l were spiked with increasing pegvisomant concentrations (9000–494 000 µg/l). Samples were analysed by the Nichols Advantage, DPC Immulite 2000, Diasorin IRMA, Beckman Access Dxl, Tosoh AIA and Wallac Delfia assays.

Results: With baseline GH <0.38 µg/l measured levels were <0.38 in all assays except Nichols, Diasorin and Beckman where GH peaked at 1.5, 9.6 and 17.7 µg/l respectively at low pegvisomant concentrations, falling thereafter. With the other two samples, measured GH levels progressively fell with increasing pegvisomant concentrations, except the Beckman assay where an increase (30.8 µg/l) was seen at a pegvisomant concentration of 9000 µg/l; and Diasorin and Tosoh where smaller increases were seen at lower pegvisomant concentrations, levels gradually falling thereafter.

Conclusion: The presence of pegvisomant resulted in artefactually low measured GH in most assays. We speculate this fall is due to assay antibody-binding pegvisomant, reducing the amount of available antibody to bind actual GH thereby producing less sandwich formation; the 'high-dose hook' effect. In most assays, this effect is modest and results in lower GH, but the level of interference makes them unsuitable for studies on the influence of pegvisomant on GH neuroregulation.

European Journal of Endocrinology 156 315–319

Introduction

Acromegaly is due to hypersecretion of growth hormone (GH) usually from a benign pituitary somatotroph adenoma. Circulating GH stimulates the production of insulin-like growth factor-I (IGF-I), the effector molecule responsible for many of the signs and symptoms. GH is a 191-residue peptide which binds to a preformed dimer of identical transmembrane cell surface receptors to induce signal activation and IGF-I generation (1). Pegvisomant is a new GH competitive receptor antagonist that has recently been licensed for use in acromegaly. It is a genetically engineered GH analogue that differs from wild-type (wt) GH by eight mutations in the region of binding site 1 (2). A single amino acid substitution in the region of binding site 2 (an alanine to glycine substitution at position 120) allows binding to the receptor dimer but prevents the induction of the conformational change necessary for

GH signal transduction and IGF-I synthesis and secretion (3). Pegylation (conjugation of PEG 5000 kDa moieties to lysines in the peptide) of the analogue reduces its clearance rate, increases circulating half-life and possibly reduces antigenicity. However, pegylation also reduces the affinity of pegvisomant for the GH receptor which means that to achieve adequate GH antagonism up to 1000-fold greater concentrations of pegvisomant are needed compared with GH. Pegvisomant has a 30-fold greater affinity for the GH-binding protein compared with the GH receptor (1, 4).

Consensus criteria suggest remission of acromegaly is achieved when there is normalisation of age- and sex-matched serum IGF-I levels with suppression of serum GH to <1 µg/l after the administration of 75 g oral glucose (5, 6). By virtue of its mechanism of action IGF-I is the sole marker of disease activity in patients receiving pegvisomant, as unlike other medical therapies it makes no attempt to reduce circulating GH levels.

Normalisation of IGF-I has been reported in 97% patients on this therapy with concomitant improvement in associated intermediary metabolic abnormalities such as glucose intolerance (7).

Pegvisomant is commenced at a starting dose of 10 mg/day increasing up to 40 mg/day as necessary to control serum IGF-I levels. Equivalent serum pegvisomant concentrations have been measured at up to 50 000 µg/l with these doses (8). Serum levels increase further (up to 80 000 µg/l) with the addition of octreotide therapy (8). Other studies have confirmed the high pegvisomant concentrations required to achieve GH antagonism with mean doses of around 16 mg/day producing mean plasma pegvisomant concentrations of around 13 330 µg/l (9).

Although GH cannot be used as a measure of disease activity, it may still be measured in research for studies of GH neuroregulation. There is also the worry that it may be unintentionally measured and clinical decisions made upon its results. Owing to its high structural homology to GH, the presence of pegvisomant in serum is likely to result in interference resulting in inaccurate GH estimations when measured using conventional assays. Special GH assays have been developed eliminating any interference and cross-reactivity, however, this is only available for research purposes (10, 11).

We aimed to investigate the effect of pegvisomant on GH measurement using six commonly available commercial assays.

Methods

A total of 20 mg pegvisomant powder was dissolved in 2 ml de-ionised water by mixing at room temperature for 10 min to give a stock solution of 10 mg/ml (10 000 µg/ml). Three pooled serum samples of different GH concentrations (GH <0.38, approximately 3.9 and 7.7 µg/l as measured on the Nichols Advantage (Nichols Institute Diagnostics, San Clemente, CA 92673, USA)) were prepared and ‘spiked’ with the

stock solution to give increasing pegvisomant concentrations of 9000, 20 000, 41 000, 82 000 and 494 000 µg/l. Samples were collected from patients who had never received treatment with pegvisomant. Aliquots of the preparations were stored at –20 °C prior to dispatch to the participating laboratories. Analyses were performed in singlicate.

GH was analysed in each sample using widely available commercial assays: the Nichols Advantage, DPC Immulite 2000 (Diagnostics Products Corporation, Gwynned, UK), Diasorin IRMA (DiaSorin Ltd, Wokingham, UK), Beckman Access Dxl (Beckman Coulter UK Ltd, High Wycombe, UK), Tosoh AIA (TOSOH Bioscience, Inc., San Francisco, CA 94080, USA) and Wallac Delfia (Perkin–Elmer Life and Analytical Sciences, Turku, Finland; Table 1).

All assays are solid phase, two-site immunometric sandwich assays (Table 1). Serum samples containing GH are incubated with an immobilised antibody (monoclonal) directed against a specific site on the GH molecule and a labelled second antibody (monoclonal/polyclonal) used as a tracer directed against a separate antigenic site. During incubation, the tracer binds to the solid phase following which the amount of bound labelled antibody is proportional to the concentration of GH in the sample. All assays are calibrated to WHO NIBSC standards.

Results

Sample 1 (Baseline GH <0.4 µg/l)

Levels remained <0.4 µg/l in three of the assays (Wallac, Tosoh and DPC Immulite) at all concentrations of pegvisomant. For the Beckman Access Dxl assay, measured GH levels peaked at 17.7 µg/l at a pegvisomant concentration of 20 000 µg/l; for the Diasorin assay GH peaked at 9.8 µg/l at a pegvisomant concentration of 9000 µg/l and in the Nichols assay GH peaked at 1.5 µg/l at a pegvisomant concentration

Table 1 Growth hormone assays used.

Assay	Assay design	Incubation time (min)	Antibodies used	Analytical sensitivity (manufacturer provided; ng/ml)	Intraassay variation (% CV)	WHO calibration
Nichols Advantage	Simultaneous	60	One mouse monoclonal and one goat polyclonal	0.1	<6% at GH >2 ng/ml	1st IS 80/505
DPC Immulite 2000	Sequential	30	One murine monoclonal and one rabbit polyclonal	0.01	<7% at GH >2.5 ng/ml	2nd IS 98/574
Diasorin IRMA	Simultaneous	90	Two mouse monoclonal	0.2	<6% at GH >1 ng/ml	1st IS 80/505
Beckman Access Dxl	Simultaneous	42	One mouse monoclonal and one goat polyclonal	0.003	<8% at GH >0.1 ng/ml	1st IS 80/505
Tosoh AIA	Sequential	30	Two mouse monoclonal	0.07	<6% at GH >2 ng/ml	2nd IS 98/574
Wallac Delfia	Simultaneous	120	Two mouse monoclonal	0.01	<2.5% at GH >0.4 ng/ml	1st IS 80/505

of 20 000 µg/l. In all of these assays, measured GH levels then fell progressively with further increases in pegvisomant concentrations (Fig. 1).

Sample 2 (Baseline GH ~ 3.9 µg/l)

For most assays, measured GH fell as the pegvisomant concentration rose. Exceptions were the Beckman Access Dxl assay where a ninefold increase in measured GH was seen at 30 µg/l and the Diasorin assay where measured levels increased to 10 µg/l, in both cases at pegvisomant concentrations of 9000 µg/l. Modest increases were also seen in the Tosoh assay. As before GH levels then fell progressively as the pegvisomant concentration increased (Fig. 2).

Sample 3 (Baseline GH ~ 7.7 µg/l)

Results were similar to those reported when baseline GH was ~ 3.9 µg/l where a progressive fall in measured GH was seen with increasing pegvisomant concentrations. However a fourfold rise in measured GH was seen for the Beckman Access Dxl assay to 31.5 µg/l at a pegvisomant concentration of 9000 µg/l and the Diasorin assay peaked at 8.9 µg/l at the same pegvisomant concentration with reduction in GH levels thereafter (Fig. 3).

Discussion

We have investigated the effect of differing pegvisomant concentrations on GH measurement using widely available commercial assays (Nichols Advantage, DPC Immulite 2000, Diasorin IRMA, Beckman Access Dxl, Tosoh AIA and Wallac Delfia). Baseline differences are seen in GH levels which reflect the known assay bias. Results demonstrate that in most GH assays the

Figure 2 Results of spiking increasing concentrations of pegvisomant into a sample containing ~3.9 µg/l GH.

presence of pegvisomant leads to a reduction in measured plasma GH levels with a progressive decline seen at higher pegvisomant concentrations. In three assays (the Nichols Advantage, Beckman Access Dxl and Diasorin IRMA), the progressive fall in GH levels was preceded by an initial increase. These data confirm our knowledge that GH cannot be reliably measured in patients on pegvisomant in commercially available assays, but contradicts previous predictions that cross-reactivity would result in artefactually high levels of GH.

We postulate that one of three mechanisms may be important in the effect of pegvisomant on observed GH concentrations:

- 1 As stated before, each molecule of pegvisomant is pegylated (PEG). PEG has historically been used in immunoassays as part of second antibody separation procedures where it works not by binding antibody but enhancing antibody–antigen interactions (by

Figure 1 Results of spiking increasing concentrations of pegvisomant into a sample containing <0.4 µg/l GH.

Figure 3 Results of spiking increasing concentrations of pegvisomant into a sample containing ~7.7 µg/l GH.

removing water/hydrophilic residues). Although its presence would not actually bind the antigen or antibody causing any interference, it is possible that the sheer concentration of PEG present produces steric hindrance in the sandwich complex binding. This is particularly likely at the highest concentrations of pegvisomant (494 000 µg/l) where there are four to six molecules of PEG present per molecule of pegvisomant. This study demonstrates that the effect of PEG in any given assay system is unpredictable.

- 2 Pegvisomant could be acting as an antigen binding to one, but not both, of the antibodies. This would prevent sandwich formation and therefore decrease measured GH levels as seen in some assays with increasing pegvisomant concentrations. Supporting this theory are the findings by Thorner *et al.* (10), who employed two strategies for measuring GH levels in healthy young men following the administration of pegvisomant in doses up to 1 mg/kg. GH was measured using a modified Nichols chemiluminescence assay (empirically corrected for pegvisomant cross-reactivity), and a direct GH two-site immunoassay using two monoclonal antibodies with high affinity for GH but no cross-reactivity with PEG up to a concentration of 50 000 µg/l. Concordance in GH levels was found between the assays with no significant change in GH levels at any dose.
- 3 Owing to the high structural homology to GH, pegvisomant could act as an antigen binding to both antibodies and permitting sandwich formation. Therefore, measured GH could increase in the presence of pegvisomant. However, the 'high-dose hook' effect (excess concentration of pegvisomant results in saturation of available antibody sites resulting in failure of GH sandwich complex formation) may act to decrease observed GH as pegvisomant concentration increases. This could explain the pattern seen in the Beckman Access Dxl and Diasorin IRMA assays. The range of pegvisomant concentrations used in this study was chosen to reflect levels achieved in clinical practise. Further studies would be necessary to explore the 'hook effect' using lower concentrations of pegvisomant.

We cannot say with confidence which of these mechanisms is applicable to any one assay – more than one may be in play in each assay. However, it should be noted that the 'high-dose hook' effect could explain all the observations, assuming that the hook point in those assays that did not show an initial increase in observed GH actually occurred at some pegvisomant concentration lower than the lowest spike.

Given the nature of interference of pegvisomant in commercial assays producing artefactually lower and higher levels of GH than the predicted excessively high levels, incorrect interpretations of results could occur.

It may be that GH levels appear of a plausible range, in keeping with what would be expected and hence are not recognised as incorrect. Therefore, if GH is to be measured it is critical that specific assays which detect only true GH levels with no cross-reactivity from the presence of pegvisomant are developed for commercial use.

In summary, we have demonstrated pegvisomant to interfere negatively with GH with lower levels measured with higher concentrations of pegvisomant. In most assays, the effect of pegvisomant at therapeutic concentrations is modest and results in lower GH, but the level of interference makes them unsuitable for studies on the influence of pegvisomant on GH neuroregulation.

References

- 1 Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ & Ho KK. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. *Journal of Clinical Endocrinology and Metabolism* 2001 **86** 1716–1723.
- 2 Kopchick JJ, Parkinson C, Stevens EC & Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. *Endocrine Reviews* 2002 **23** 623–646.
- 3 Pradhananga S, Wilkinson I & Ross RJ. Pegvisomant: structure and function. *Journal of Molecular Endocrinology* 2002 **29** 11–14.
- 4 Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Van Der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. *New England Journal of Medicine* 2000 **342** 1171–1177.
- 5 Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. *Journal of Clinical Endocrinology and Metabolism* 2000 **85** 526–529.
- 6 Trainer PJ. Editorial: acromegaly-consensus, what consensus? *Journal of Clinical Endocrinology and Metabolism* 2002 **87** 3534–3536.
- 7 Van Der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. *Lancet* 2001 **358** 1754–1759.
- 8 Van Der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA & Lamberts SW. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. *Journal of Clinical Endocrinology and Metabolism* 2001 **86** 478–481.
- 9 Parkinson C, Burman P, Messig M & Trainer PJ. Gender, body weight, disease activity, and prior radiotherapy influence the response to pegvisomant. *Journal of Clinical Endocrinology and Metabolism* 2007 **92** 190–195.
- 10 Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC & Bennett WF. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers

- serum insulin-like growth factor-I but does not acutely stimulate serum GH. *Journal of Clinical Endocrinology and Metabolism* 1999 **84** 2098–2103.
- 11 Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z & Strasburger CJ. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. *Journal of Clinical Endocrinology and Metabolism* 2001 **86** 3304–3310.
-
- Received 29 August 2006
Accepted 5 December 2006